• Biogen will present new Alzheimer’s disease study data at CTAD in Boston, November 16-19, 2026.
• Investigational diranersen’s Phase 2 CELIA update will cover longer-term efficacy, safety and biomarkers, building on results presented in July 2026.
• Leqembi presentations will examine five-year treatment outcomes and safety, alongside three-year real-world evidence on maintenance therapy and at-home subcutaneous administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290659PRIMZONEFULLFEED9855736) on October 29, 2026, and is solely responsible for the information contained therein.